BPC 157 VIAL High Purity Peptide for Research Pure Bio Labs FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner FormBlends Publishes 2026 State of Peptides Report as RFK Era HHS Signals Major Shifts for GLP 1 and Peptide Therapy Access in the United States USA Today BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved